尿路感染症に対するOfloxacin(OFLX)の臨床的検討

Abstract

新しい経口合成抗筋剤Ofloxacin (OFLX)を53名の尿路感染症患者に使用し, 臨床的検討を加えた.OFLX (600 mg/day)を35名の急性単純性膀胱炎患者には3日間以上, 18日の複雑性尿路感染症患者には副作用で投与を中止した1例を除いて5日間以上連日投与した.急性単純性膀胱炎:UTI薬効評価基準に合致した10例で総合有効率100%を得た.同定しえた26株の起炎菌はすべて消失し, 自覚症状も著明に改善した.全例に対する主治医判定では, 94.3%がきわめて有用または有用とされた.複雑性尿路感染症:5～7日間投与の11例中63.6%の膿尿の改善を認めた.UTI薬効評価基準に合致した4例では総合有効率100%を得た.同定しえた9株の起炎菌のうち7株が消失した.全例に対する主治医判定では, 38.9%がきわめて有用または有用と判定された.53例中4例に軽度の副作用を認めた

Fifty-three patients with urinary tract infections (UTI) were treated with Ofloxacin, a new oral synthetic antimicrobial agent, and its clinical efficacy was studied. Ofloxacin (600 mg/day) was administered to 35 patients with acute simple cystitis for more than three days, and to 17 patients with complicated UTI for more than five days except a case in which the treatment was interrupted for side effects. Acute simple cystitis: In ten cases meeting the criteria of UTI committee, overall effectiveness rate was 100%. All of the 26 strains isolated from 26 patients disappeared after the treatment. In all of acute simple cystitis cases, 94.3% were evaluated as excellent or as moderate by attending doctors. Complicated UTI: In 11 cases treated during five or seven days, 63.6% of patients showed improvement on pyuria. Seven out of nine strains isolated from seven patients disappeared. However, two strains of P. aeruginosa and P. cepacia persisted after the treatment. In all of the complicated UTI cases, 38.9% of patients were evaluated as excellent or as moderate by attending doctors. Some slight side effects were observed in four out of 53 cases. This study showed that Ofloxacin is effective against urinary tract infections.